Prior COVID-19 infection is associated with increased Adverse Events (AEs) after the first, but not the second, dose of the BNT162b2/Pfizer vaccine

Polack, 2020, Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine, N Engl J Med, 383, 2603, 10.1056/NEJMoa2034577 Baden, 2021, Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine, N Engl J Med., 384, 403, 10.1056/NEJMoa2035389 Kadali, 2021, Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers, Int J Infect Dis., 106, 376, 10.1016/j.ijid.2021.04.047 Krammer, 2021, Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine, N Engl J Med., 384, 1372, 10.1056/NEJMc2101667 Tré-Hardy, 2021, Reactogenicity, safety and antibody response, after one and two doses of mRNA-1273 in seronegative and seropositive healthcare workers, J Infect., 83, 237, 10.1016/j.jinf.2021.03.025 Ebinger, 2021, Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2, Nat Med., 27, 981, 10.1038/s41591-021-01325-6 Mathioudakis AG, Ghrew M, Ustianowski A et al. Self-reported real-world safety and reactogenicity of COVID-19 vaccines: An international vaccine-recipient survey. MedRxiv 2021; 2021.02.26.21252096. doi: https://doi.org/10.1101/2021.02.26.21252096. Raw, 2021, Previous COVID-19 infection, but not Long-COVID, is associated with increased adverse events following BNT162b2/Pfizer vaccination, J Infect., S0163–4453, 00277 Manisty, 2021, Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals, Lancet, 397, 1057, 10.1016/S0140-6736(21)00501-8 Saadat, 2021, Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2, JAMA, 325, 1467, 10.1001/jama.2021.3341 Prendecki, 2021, Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine, Lancet, 397, 1178, 10.1016/S0140-6736(21)00502-X Carfì, 2020, Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19, JAMA, 324, 603, 10.1001/jama.2020.12603 Bunders, 2020, Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions, Immunity, 53, 487, 10.1016/j.immuni.2020.08.003 Dolgin, 2021, Is one vaccine dose enough if you've had COVID?, What the science says. Nature., 595, 161 Food and Drug Administration. Guidance for Industry Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. 2021. https://www.fda.gov/media/73679/download (accessed July 25, 2021). National Institute of Clinical Excellence (NICE), the Scottish Intercollegiate Guidelines Network (SIGN), and the Royal College of General Practitioners (RCGP). NICE ‘long COVID’ guideline. 2021. https://www.guidelines.co.uk/infection/nice-long-covid-guideline/455728.article (accessed November 11, 2021). Freeman D, Loe BS, Chadwick A et al. COVID-19 vaccine hesitancy in the UK: the Oxford coronavirus explanations, attitudes, and narratives survey (Oceans) II. Psychol Med. 2020:1-15. doi: 10.1017/S0033291720005188. Machingaidze, 2021, Understanding COVID-19 vaccine hesitancy, Nat Med., 27, 1338, 10.1038/s41591-021-01459-7 Robertson, 2021, Predictors of COVID-19 vaccine hesitancy in the UK household longitudinal study, Brain Behav Immun., 94, 41, 10.1016/j.bbi.2021.03.008